Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Retatrutide for Knee Osteoarthritis Pain

Two phase 3 trials found larger knee-pain reductions and substantial weight loss with retatrutide versus placebo in adults with obesity.

Why we wrote this. The phase 3 pain results are easy to confuse with approval or proof of a direct joint effect. This explainer keeps the finding inside the trial population and design.

In this article (5 sections)
  1. What the two trials tested
  2. How much knee pain changed
  3. Weight loss happened alongside pain relief
  4. Safety and the limits of the result
  5. What we don't yet know

Two phase 3 trials found that adults with obesity and painful knee osteoarthritis had larger reductions in knee pain with once-weekly retatrutide than with placebo. They also lost substantially more weight. The results are encouraging, but they do not show how much of the pain change came from weight loss, a direct drug effect or other changes during treatment. Retatrutide remains investigational rather than an FDA-approved treatment.[1]

The paper, published in the New England Journal of Medicine, reports TRIUMPH-4 and the knee osteoarthritis substudy of TRIUMPH-1. Both were randomized, double-blind, placebo-controlled trials funded by Eli Lilly. They studied adults without diabetes who had a body mass index of at least 27 and painful knee osteoarthritis. That is a defined trial population, not everyone with knee pain or everyone seeking weight loss.[1]

What the two trials tested

TRIUMPH-4 randomized 445 participants to 9 mg or 12 mg of subcutaneous retatrutide once weekly, or placebo, and assessed outcomes at 68 weeks. Its two primary outcomes were change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score and percentage change in body weight. The WOMAC pain scale ran from 0 to 10, with a higher score indicating worse pain.[1] The public trial record confirms the phase 3, randomized, parallel and double-blind design, along with the actual enrollment of 445.[2]

The knee osteoarthritis substudy within TRIUMPH-1 included 574 participants and assessed pain at 80 weeks. Participants received 4 mg, 9 mg or 12 mg of retatrutide once weekly, or placebo. The broader TRIUMPH-1 registry covers several study components, so its overall enrollment is larger than the osteoarthritis subgroup reported in the paper. The registry also identifies the study as randomized, double-blind and placebo-controlled.[1][3]

The trial schedules are evidence about what researchers administered, not dosing instructions. Anyone looking for background on the molecule can read our plain-English retatrutide guide. Its investigational status also matters when interpreting online availability claims, including those aimed at readers in the United States.

How much knee pain changed

In TRIUMPH-4, mean WOMAC pain scores fell by 3.96 points with 9 mg and 3.74 points with 12 mg at week 68. The placebo group improved by 2.12 points. The estimated differences from placebo were 1.83 points for 9 mg and 1.61 points for 12 mg in favor of retatrutide. Both confidence intervals excluded zero.[1]

In the TRIUMPH-1 osteoarthritis substudy at week 80, pain scores fell by 3.22 points with 4 mg, 3.48 points with 9 mg and 3.64 points with 12 mg, compared with 1.87 points on placebo. The estimated differences from placebo were 1.35, 1.61 and 1.77 points, respectively. The intention-to-treat analyses also favored retatrutide, although the estimated differences were somewhat smaller.[1]

The placebo groups improved too. That is common in pain trials and is one reason to focus on the between-group difference rather than only the change seen among treated participants. The results also do not justify assuming that the highest dose was always the best choice. In TRIUMPH-4, the reported mean pain reduction was not larger with 12 mg than with 9 mg.

Weight loss happened alongside pain relief

TRIUMPH-4 participants lost an average of 20.0% of body weight with 9 mg and 23.7% with 12 mg at week 68, compared with 4.6% with placebo. The corresponding differences from placebo were 15.4 and 19.2 percentage points.[1] Those are group averages. They do not predict an individual participant's weight or pain response.

Knee loading can change when body weight changes, so weight loss is a plausible contributor to pain improvement. The paper's abstract does not establish how much of the pain effect was mediated by weight loss, nor whether retatrutide had a separate effect on osteoarthritis symptoms. A placebo-controlled trial can show that outcomes differed between groups. Explaining the full pathway requires additional analyses.

Safety and the limits of the result

The most common adverse events in both trials were gastrointestinal. Serious adverse events were more common with retatrutide than with placebo.[1] Those findings should remain beside the efficacy numbers. The abstract does not provide enough detail to compare every specific serious event, timing pattern or reason for treatment discontinuation.

Eligibility was selective. TRIUMPH-4 required adults with obesity or overweight, knee pain lasting more than 12 weeks, frequent pain in the previous month, moderate radiographic changes and clinical criteria for osteoarthritis. It excluded diabetes and several recent joint procedures or injections.[2] The findings therefore should not be transferred automatically to people with mild radiographic disease, another cause of knee pain, diabetes or a recent joint intervention.

The trials compared retatrutide with placebo, not with established osteoarthritis treatments or another weight-management medicine. They cannot show that retatrutide is superior to physical therapy, anti-inflammatory treatment, joint injections, surgery or an approved obesity medicine. Cross-trial comparisons would also be unreliable because populations, outcome definitions and follow-up periods differ.

What we don't yet know

We do not yet know whether pain benefits persist after treatment stops, whether structural joint damage changes, or which patients are most likely to benefit without unacceptable adverse effects. The reported follow-up was long enough to measure outcomes at 68 or 80 weeks, but it does not answer questions about several years of use.

The results also leave the mechanism of pain improvement unresolved. Future reporting may clarify mediation by weight loss, physical function, analgesic use, discontinuations and the nature of serious adverse events. Independent replication would help because the sponsor funded the trials and developed the medicine.

For now, the defensible conclusion is narrow: in two sponsor-funded phase 3 trials of adults without diabetes who had obesity or overweight and painful knee osteoarthritis, retatrutide produced larger average improvements in pain than placebo while producing substantial weight loss. That finding is not an approval, a personal prognosis or a treatment recommendation.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did retatrutide reduce knee osteoarthritis pain in the trials?

Yes. Average WOMAC pain scores improved more with retatrutide than with placebo in both phase 3 trials. The results apply to the selected trial populations and do not predict an individual's response.

Was the pain improvement caused by weight loss?

Weight loss is a plausible contributor, but the published abstract does not establish how much of the pain improvement came from lower body weight or from another pathway.

What side effects were reported?

Gastrointestinal events were the most common adverse events. Serious adverse events were more common with retatrutide than with placebo, although the abstract does not list every event in detail.

Is retatrutide approved for knee osteoarthritis?

No. These are clinical-trial findings for an investigational medicine. A positive phase 3 result does not by itself create FDA approval or establish that the treatment is suitable for a particular person.

Sources

  1. [1]Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity, PMID 43001755Tier 1 · primary↩
  2. [2]ClinicalTrials.gov record for TRIUMPH-4, NCT05931367Tier 1 · primary↩
  3. [3]ClinicalTrials.gov record for TRIUMPH-1, NCT05929066Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.